Histone Deacetylase Inhibitors

Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors. It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma ...Wikipedia

Manufacturer's Website: Beleodaq                                                                     Average retail cost: $1,800/vial

Romidepsin, also known as Istodax, is an anticancer agent used in cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs)...Wikipedia

Manufacturer's Website: Istodax                                                                       Average retail cost: $3,000/vial

Panobinostat (trade name Farydak) is a drug by Novartis for the treatment of various cancers. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor)...Wikipedia

Manufacturer's Website: Farydak                                                                     Average retail cost: $7,500/vial

Vorinostat (rINN) also known as suberanilohydroxamic acid (suberoyl+anilide+hydroxamic acid abbreviated as SAHA) is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities. Vorinostat is marketed under the name Zolinza (/zoʊˈlɪnzə/ zoh-LIN-zə) by Merck for the treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after two systemic therapies ...Wikipedia

Manufacturer's Website: Zolinza                                                                     Average retail cost: $12,600/vial